Examples of using Composite endpoint in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Composite Endpoint.
Secondary composite endpoints.
The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint.
Primary Composite Endpoint at Week 32.
Relative to placebo, Xarelto significantly reduced the primary composite endpoint of CV death, MI or stroke.
Primary composite endpoint of CV death and heart failure hospitalisations.
Response assessment was based on a composite endpoint defined as above.
The RRR for the composite endpoint from 1 to 360 days(17% RRR) and from 361 days and onwards(16% RRR) was similar.
The efficacy results for≥50% of responder days(primary composite endpoint) over 6 months are shown in Table 2.
This was a composite endpoint which had the following skeletal related events(SREs) as sub-components.
ACUITY trial; 30-day and 1-year risk differences for the composite endpoint and its components for the overall population ITT.
Treatment with losartan resulted in a 13.0% risk reduction(p=0.021, 95% confidence interval 0.77-0.98)compared with atenolol for patients reaching the primary composite endpoint.
Treatment effect on the primary composite endpoint, its components and secondary endpoints.
The study met its primary objective anda higher proportion of patients in the Jakavi group achieved the primary composite endpoint and each of its individual components.
The trial had a primary composite endpoint of CV death, nonfatal myocardial infarction and nonfatal stroke.
Relative to ASA alone,ticagrelor 60 mg twice daily significantly reduced the primary composite endpoint of CV death, MI and stroke.
Cumulative rates for this composite endpoint over 3 years were 2.3%(21/ 933 subjects) and 1.9%(12/ 628 subjects).
The results showed that the treatment with Losartan(327 events) as compared with placebo(359 events) resulted in a 16.1% risk reduction(p 0.022)in the number of patients reaching the primary composite endpoint.
The result of the key secondary composite endpoint is primarily attributed to effects on worsening kidney function and medically significant kidney pain.
In the cohort of post-MI or PAD patients with no history of stroke or TIA,the findings for the primary and key secondary composite endpoints are consistent with the overall population see Figure 1 and Table 4.
The primary endpoint of the study was a composite endpoint of doubling of the serum creatinine end- stage renal failure(need for dialysis or transplantation) or death.
However, subjects on saxagliptin with a history of heart failure or impaired renal function at baseline were not at an increased risk relative to placebo for the primary or secondary composite endpoints or all-cause mortality.
In the PreSAP trial,the relative risk compared to placebo for this same composite endpoint(adjudicated) was 1.2(95% CI 0.6- 2.4) with celecoxib 400 mg once daily compared to placebo.
Valsartan was also effective in prolonging the time to and reducing cardiovascular mortality, hospitalisation for heart failure, recurrent myocardial infarction, resuscitated cardiac arrest,and non-fatal stroke secondary composite endpoint.
The relative risk compared to placebo for a similar composite endpoint(CV death, MI, stroke) was 1.14(95% CI 0.61- 2.12) with celecoxib 200 mg twice daily.
The primary efficacy endpoint was a composite endpoint(SLE Responder Index) that defined response as meeting each of the following criteria at Week 52 compared with baseline.
The efficacy failure rate as measured by the composite endpoint of death, graft loss, centrally read BPAR and loss to follow-up was 18.3% in the Envarsus group and 19.6% in the Prograf group.
The efficacy failure rate as measured by the composite endpoint of death, graft loss, locally read BPAR and loss to follow-up was 2.5% in both the Envarsus and Prograf groups.
The primary efficacy endpoint, puncture-free survival, was a composite endpoint defined as the time to first need for therapeutic ascites puncture or death, whichever occurred first identical to the pivotal study.
After 12 months of treatment,the percentage of patients meeting the primary composite endpoint(composed of all four components mentioned in Table 4) was 84.8%[95% confidence interval 76.2%- 91.3%] for the Cerdelga group compared to 93.6%[95% confidence interval 82.5%- 98.7%] for the Cerezyme group.